Septic Shock - Pipeline Review, H1 2015

Published: Apr, 2015 | Pages: 77 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Septic Shock - Pipeline Review, H1 2015

Summary 

Global Markets Direct's, 'Septic Shock - Pipeline Review, H1 2015', provides an overview of the Septic Shock's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Septic Shock, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Septic Shock and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Septic Shock
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Septic Shock and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Septic Shock products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Septic Shock pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reason To Buy 

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Septic Shock
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Septic Shock pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Septic Shock Overview 9
Therapeutics Development 10
Pipeline Products for Septic Shock - Overview 10
Pipeline Products for Septic Shock - Comparative Analysis 11
Septic Shock - Therapeutics under Development by Companies 12
Septic Shock - Therapeutics under Investigation by Universities/Institutes 13
Septic Shock - Pipeline Products Glance 14
Clinical Stage Products 14
Early Stage Products 15
Unknown Stage Products 16
Septic Shock - Products under Development by Companies 17
Septic Shock - Products under Investigation by Universities/Institutes 19
Septic Shock - Companies Involved in Therapeutics Development 20
Adrenomed AG 20
Compugen Ltd. 21
Ferring International Center S.A. 22
Huons Co., Ltd. 23
InflaRx GmbH 24
Lixte Biotechnology Holdings, Inc. 25
Noxxon Pharma AG 26
Orion Oyj 27
Pharmazz, Inc. 28
Spider Biotech 29
Takeda Pharmaceutical Company Limited 30
XImmune AB 31
Septic Shock - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Target 33
Assessment by Mechanism of Action 35
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
adrecizumab - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
AM-12 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
BC-1215 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
BTZO-2 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
centhaquine - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
CGEN-25068 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
HBN-1 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
HBN-3 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
HBN-4 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
HU-003 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
IFX-1 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
LB-100 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
LB-102 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
LB-1148 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
levosimendan - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
MFH-147 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
NOXD-20 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Proteins to Inhibit Nuclear Factor Kappa B for Septic Shock - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
R-190 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
SB-056 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
selepressin - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Small Molecules to Antagonize TLR-4 for Septicemia and Septic Shock - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
SP-14 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
SP-9 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Synthetic Peptides for Inflammation and Infectious Disorders - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Septic Shock - Recent Pipeline Updates 69
Septic Shock - Dormant Projects 72
Septic Shock - Discontinued Products 73
Septic Shock - Product Development Milestones 74
Featured News & Press Releases 74
Feb 02, 2015: Leading BioSciences Receives FDA IND Clearance To Proceed With A Randomized, Multi-Center Phase 2 Clinical Trial Using LB1148 To Treat Septic Shock 74
Jan 02, 2013: Adrenomed Develops New Drug To Reduce Mortality From Septic Shock 75
Appendix 76
Methodology 76
Coverage 76
Secondary Research 76
Primary Research 76
Expert Panel Validation 76
Contact Us 76
Disclaimer 77

List of Tables

Number of Products under Development for Septic Shock, H1 2015 10
Number of Products under Development for Septic Shock - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 12
Number of Products under Investigation by Universities/Institutes, H1 2015 13
Comparative Analysis by Clinical Stage Development, H1 2015 14
Comparative Analysis by Early Stage Development, H1 2015 15
Comparative Analysis by Unknown Stage Development, H1 2015 16
Products under Development by Companies, H1 2015 17
Products under Development by Companies, H1 2015 (Contd..1) 18
Products under Investigation by Universities/Institutes, H1 2015 19
Septic Shock - Pipeline by Adrenomed AG, H1 2015 20
Septic Shock - Pipeline by Compugen Ltd., H1 2015 21
Septic Shock - Pipeline by Ferring International Center S.A., H1 2015 22
Septic Shock - Pipeline by Huons Co., Ltd., H1 2015 23
Septic Shock - Pipeline by InflaRx GmbH, H1 2015 24
Septic Shock - Pipeline by Lixte Biotechnology Holdings, Inc., H1 2015 25
Septic Shock - Pipeline by Noxxon Pharma AG, H1 2015 26
Septic Shock - Pipeline by Orion Oyj, H1 2015 27
Septic Shock - Pipeline by Pharmazz, Inc., H1 2015 28
Septic Shock - Pipeline by Spider Biotech, H1 2015 29
Septic Shock - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 30
Septic Shock - Pipeline by XImmune AB, H1 2015 31
Assessment by Monotherapy Products, H1 2015 32
Number of Products by Stage and Target, H1 2015 34
Number of Products by Stage and Mechanism of Action, H1 2015 36
Number of Products by Stage and Route of Administration, H1 2015 38
Number of Products by Stage and Molecule Type, H1 2015 40
Septic Shock Therapeutics - Recent Pipeline Updates, H1 2015 69
Septic Shock - Dormant Projects, H1 2015 72
Septic Shock - Discontinued Products, H1 2015 73